Study of Oral Caffeine to Reduce Severity of Acute Migraine Attacks in Adults Up to 60 Years at Ain Shams University Hospitals

What this Trial Is About

Researchers are evaluating the use of caffeine extracted from green tea to reduce the severity of acute migraine attacks in adults aged 18 to 60 years. This Phase 4 randomized controlled trial compares the effects of oral caffeine intake with standard treatments for migraines, such as NSAIDs, triptans, or acetaminophen. The study aims to understand if adding caffeine tablets can help lessen migraine pain intensity measured by the Visual Analogue Scale VAS. Participants are randomly assigned to either receive caffeine tablets 200 mg in addition to their standard migraine treatment or to continue with standard treatment alone. The trial is conducted at the Headache and Neurology Outpatients Clinic of Ainshams University Hospitals and lasts for three years. The caffeine group receives caffeine tablets alongside their usual medications, while the control group receives only the standard migraine medications. During the study, participants will be monitored for changes in migraine severity and pain reduction at regular intervals using the VAS score. Researchers will assess the effectiveness of caffeine in easing migraine attacks over the three-year period. Safety and adherence to treatments will be observed throughout, with ongoing evaluations to ensure participant well-being and to record any changes in migraine symptoms.

Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals